Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Baseline Clinical Characteristics According to MAFLD Status(N = 98,685)

From: Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study

 

Total

Non-MAFLD

MAFLD

p-value

Participants (n)

98,685

67,930

30,755

 

Age,year

51.88 ± 12.64

51.48 ± 13.12

52.75 ± 11.49

< 0.01

Male, N(%)

78,893(79.94)

53,697(79.05)

25,196(81.92)

< 0.01

Mean follow-up time,year

14.01(13.63–14.19)

14.00(13.63–14.19)

14.01(13.61–14.20)

0.24

SBP, mmHg

131.09 ± 21.05

128.24 ± 20.49

137.36 ± 20.92

< 0.01

DBP, mmHg

83.51 ± 11.79

81.78 ± 11.37

87.35 ± 11.79

< 0.01

TG, mmol/L

1.27(0.90–1.93)

1.12(0.80–1.60)

1.77(1.23–2.67)

< 0.01

BMI, Kg/m2

25.05 ± 3.49

23.94 ± 3.05

27.50 ± 3.14

< 0.01

FBG, mmol/L

5.11(4.66–5.71)

5.04(4.60–5.56)

5.36(4.81–6.16)

< 0.01

HDL-C, mmol/L

1.50(1.28–1.77)

1.51(1.29–1.77)

1.48(1.26–1.74)

< 0.01

WC,cm

   

< 0.01

female

83.06 ± 10.73

80.24 ± 10.01

90.27 ± 9.01

 

males

83.06 ± 9.57

85.67 ± 9.02

93.24 ± 8.62

 

Hs-CRP,mg/L

0.80(0.30–2.20)

0.69(0.26–1.82)

1.20(0.50–3.01)

< 0.01

Current smoker, N (%)

34,018(34.47)

23,311(34.32)

10,707(34.81)

0.13

Current drinker, N (%)

40,818(41.36)

27,480(40.45)

13,338(43.37)

< 0.01

Physical activity, N(%)

90,075(91.28)

61,874(91.08)

28,201(91.70)

< 0.01

Education level, N(%)

   

< 0.01

≤junior high school

78,655(79.70)

53,970(79.45)

24,685(80.26)

 

≥senior high school

20,030(20.30)

13,960(20.55)

6070(19.74)

 

Salt level, g/d

   

< 0.01

< 6

9163(9.29)

6472(9.53)

2691(8.75)

 

6–10

78,843(79.89)

54,436(80.14)

24,407(79.36)

 

> 10

10,679(10.82)

7022(10.34)

3657(11.89)

 

Antihypertensive treatment, N(%)

11,029(11.18)

5762(8.48)

5267(17.13)

< 0.01

Antidiabetic treatment, N (%)

2420(2.45)

1221(1.80)

1199(3.90)

< 0.01

Lipid-lowering treatment, N (%)

925(0.94)

431(0.63)

494(1.61)

< 0.01

hypertension

37,128(37.62)

21,380(31.47)

15,748(51.20)

< 0.01

diabetes

9336(9.46)

4278(6.30)

5058(16.45)

< 0.01

  1. Data were present as n (%), mean ± SD, or median (P25, P75) according to variable category. Pearson’s chi-square test, Student T test, or Kruskal-Wallis test was used to compare differences between groups properly
  2. Abbreviations: BMI, body mass index; FBG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference; HDL-C, high-density lipoprotein; TG, triglyceride
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us